Please assess the completion status of the following clinical trial:

Trial Title: A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Well-demarcated area of GA secondary to AMD~* Women of childbearing potential and men must agree to use adequate contraception for at least 30 days after fluorescein dye administration~* The study is recruiting participants in two different cohorts:~Cohort 1: Participants with unilateral GA OR Cohort 2: Participants with GA in one eye and CNV (active or treated) with or without GA, in the contralateral eye~Exclusion Criteria:~* Previous participation in any studies of investigational drugs for GA / dry AMD (exception for studies of vitamins and minerals)~* GA in either eye due to causes other than AMD~* History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD~* Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy~* Any ocular/systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments.~* Requirement for continuous use of therapy indicated in Prohibited Therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Geographic Atrophy Participants (Type: None): Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).